These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 24531711)

  • 41. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis.
    Bi X; Hameed M; Mirani N; Pimenta EM; Anari J; Barnes BJ
    Breast Cancer Res; 2011; 13(6):R111. PubMed ID: 22053985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
    Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
    Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
    [TBL] [Abstract][Full Text] [Related]  

  • 43. p53R172H and p53R245W Hotspot Mutations Drive Distinct Transcriptomes in Mouse Mammary Tumors Through a Convergent Transcriptional Mediator.
    McDaniel JM; Morrissey RL; Dibra D; Patel LR; Xiong S; Zhang Y; Chau GP; Su X; Qi Y; El-Naggar AK; Lozano G
    Cancer Res Commun; 2024 Aug; 4(8):1991-2007. PubMed ID: 38994678
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer.
    Liu JC; Granieri L; Shrestha M; Wang DY; Vorobieva I; Rubie EA; Jones R; Ju Y; Pellecchia G; Jiang Z; Palmerini CA; Ben-David Y; Egan SE; Woodgett JR; Bader GD; Datti A; Zacksenhaus E
    Cell Rep; 2018 Apr; 23(1):112-126. PubMed ID: 29617654
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models.
    Melchor L; Molyneux G; Mackay A; Magnay FA; Atienza M; Kendrick H; Nava-Rodrigues D; López-García MÁ; Milanezi F; Greenow K; Robertson D; Palacios J; Reis-Filho JS; Smalley MJ
    J Pathol; 2014 Jun; 233(2):124-37. PubMed ID: 24615332
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.
    Muggerud AA; Rønneberg JA; Wärnberg F; Botling J; Busato F; Jovanovic J; Solvang H; Bukholm I; Børresen-Dale AL; Kristensen VN; Sørlie T; Tost J
    Breast Cancer Res; 2010; 12(1):R3. PubMed ID: 20056007
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells.
    Ryan D; Paul BT; Koziol J; ElShamy WM
    Breast Cancer Res; 2019 Apr; 21(1):53. PubMed ID: 31014367
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population.
    Korkaya H; Kim GI; Davis A; Malik F; Henry NL; Ithimakin S; Quraishi AA; Tawakkol N; D'Angelo R; Paulson AK; Chung S; Luther T; Paholak HJ; Liu S; Hassan KA; Zen Q; Clouthier SG; Wicha MS
    Mol Cell; 2012 Aug; 47(4):570-84. PubMed ID: 22819326
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.
    Zheng X; Huang M; Xing L; Yang R; Wang X; Jiang R; Zhang L; Chen J
    Mol Cancer; 2020 Apr; 19(1):73. PubMed ID: 32264877
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Roles of STAT3/SOCS3 pathway in regulating the visual function and ubiquitin-proteasome-dependent degradation of rhodopsin during retinal inflammation.
    Ozawa Y; Nakao K; Kurihara T; Shimazaki T; Shimmura S; Ishida S; Yoshimura A; Tsubota K; Okano H
    J Biol Chem; 2008 Sep; 283(36):24561-70. PubMed ID: 18614536
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Status of Stat3 in an ovalbumin-induced mouse model of asthma: analysis of the role of Socs3 and IL-6.
    Paul B; Mishra V; Chaudhury B; Awasthi A; Das AB; Saxena U; Saxena A; Chauhan LK; Kumar P; Raisuddin S
    Int Arch Allergy Immunol; 2009; 148(2):99-108. PubMed ID: 18799889
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.
    Khurana A; McKean H; Kim H; Kim SH; mcguire J; Roberts LR; Goetz MP; Shridhar V
    Breast Cancer Res; 2012 Mar; 14(2):R43. PubMed ID: 22410125
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An in vitro system to characterize prostate cancer progression identified signaling required for self-renewal.
    Salah M; Nishimoto Y; Kohno S; Kondoh A; Kitajima S; Muranaka H; Nishiuchi T; Ibrahim A; Yoshida A; Takahashi C
    Mol Carcinog; 2016 Dec; 55(12):1974-1989. PubMed ID: 26621780
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 55. IL-6-mediated cross-talk between human preadipocytes and ductal carcinoma in situ in breast cancer progression.
    Kim HS; Jung M; Choi SK; Woo J; Piao YJ; Hwang EH; Kim H; Kim SJ; Moon WK
    J Exp Clin Cancer Res; 2018 Aug; 37(1):200. PubMed ID: 30134951
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Suppression of SOCS3 in macrophages prevents cancer metastasis by modifying macrophage phase and MCP2/CCL8 induction.
    Hiwatashi K; Tamiya T; Hasegawa E; Fukaya T; Hashimoto M; Kakoi K; Kashiwagi I; Kimura A; Inoue N; Morita R; Yasukawa H; Yoshimura A
    Cancer Lett; 2011 Sep; 308(2):172-80. PubMed ID: 21624767
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long non-coding RNA ZEB2-AS1 promotes the proliferation, metastasis and epithelial mesenchymal transition in triple-negative breast cancer by epigenetically activating ZEB2.
    Zhang G; Li H; Sun R; Li P; Yang Z; Liu Y; Wang Z; Yang Y; Yin C
    J Cell Mol Med; 2019 May; 23(5):3271-3279. PubMed ID: 30825262
    [TBL] [Abstract][Full Text] [Related]  

  • 59. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.
    Zheng H; Ying H; Yan H; Kimmelman AC; Hiller DJ; Chen AJ; Perry SR; Tonon G; Chu GC; Ding Z; Stommel JM; Dunn KL; Wiedemeyer R; You MJ; Brennan C; Wang YA; Ligon KL; Wong WH; Chin L; DePinho RA
    Nature; 2008 Oct; 455(7216):1129-33. PubMed ID: 18948956
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals.
    Evans MK; Yu CR; Lohani A; Mahdi RM; Liu X; Trzeciak AR; Egwuagu CE
    Oncogene; 2007 Mar; 26(13):1941-8. PubMed ID: 17001312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.